EURURO Vol. 71 No. 4

517

Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal Ultrasound fusion versus Cognitive Registration. Is There a Preferred Technique?

O. Wegelin, H.H.E. van Melick, L. Hooft, J.L.H.R. Bosch, H.B. Reitsma, J.O. Barentsz, D.M. Somford

Based on this comprehensive review of the literature magnetic resonance imaging

(MRI)-guided biopsy had similar overall prostate cancer detection rates compared

with transrectal ultrasound-guided biopsy, increased rates of clinically significant

cancer, and decreased rates of clinically insignificant cancer. In-bore MRI target

biopsy has a superior overall prostate cancer detection compared with cognitively

registered target biopsy. MRI-transrectal ultrasound fusion target biopsy and in-bore

MRI target biopsy have similar detection rates. The impact of lesion characteristics

such as size and localisation could not be assessed.

532

Magnetic Resonance Imaging–targeted Prostate Biopsies: Is the Right Technique the Right Question?

M.R. Cooperberg

534

Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial

A. Heidenreich, S. Chowdhury, L. Klotz, D.R. Siemens, A. Villers, C. Ivanescu, S. Holmstrom,

B. Baron, F. Wang, P. Lin, N.D. Shore

Enzalutamide provides a health-related quality of life benefit compared with

bicalutamide in patients with asymptomatic or mildly symptomatic metastatic

castration-resistant prostate cancer.

543

The Effect of Enzalutamide and Bicalutamide on Patient-reported Quality of Life Outcomes: Results from the TERRAIN Study

M.D. Tyson, A. Bryce

545

Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy

G. Gakis, P.C. Black, B.H. Bochner, S.A. Boorjian, A. Stenzl, G.N. Thalmann, W. Kassouf

Secondary tumors of the remnant urothelium after radical cystectomy occur in

approximately 4–10% of patients. Since many of these patients have an impaired

prognosis due to delayed diagnosis, surveillance of patients with histological

features of pan-urothelial disease may improve timely detection and treatment.

558

Facing the Fate of the Remnant Urothelium After Radical Cystectomy: There Is Room for Improvement

M.W. Vetterlein, F.K.-H. Chun, L.A. Kluth

560

Radical Nephrectomy With or Without Lymph Node Dissection for Nonmetastatic Renal Cell Carcinoma: A Propensity Score-based Analysis

B. Gershman, R.H. Thompson, D.M. Moreira, S.A. Boorjian, M.K. Tollefson, C.M. Lohse,

B.A. Costello, J.C. Cheville, B.C. Leibovich

Lymph node dissection was not associated with improved oncologic outcomes

among all patients undergoing radical nephrectomy or among patients at increased

risk of nodal disease. These findings do not support a therapeutic benefit to lymph

node dissection in patients with nonmetastatic renal cell carcinoma.

568

The Role of Lymphadenectomy for Renal Cell Carcinoma: Are we any Closer to an Answer?

J.R. Porter

e u r o p e a n u r o l o g y , vo l . 7 1 , n o . 4 , A p r i l 2 0 1 7

Urothelial Cancer

Kidney Cancer

Prostate Cancer